Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Gamifant Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy 2026D0077L

    Gamifant (emapalumab-lzsg) Coverage

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0077L alerts

    Get alerted when Policy 2026D0077L changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for Gamifant administered for primary hemophagocytic lymphohistiocytosis (HLH) or HLH/macrophage activation syndrome (MAS) associated with Still's disease for UnitedHealthcare Commercial and Individual Exchange benefit plans.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyGamifant (emapalumab-lzsg) Coverage
    Policy CodePolicy 2026D0077L
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records, such as chart notes and laboratory values, confirming the applicable diagnosis and required clinical or laboratory criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was transferred to a shared template applicable to UnitedHealthcare Commercial and Individual Exchange benefit plans.

    The policy added an Application section identifying UnitedHealthcare Commercial and Individual Exchange benefit plans.

    The Clinical Evidence and References sections were updated to reflect current information.

    Previous policy versions 2026D0077K and IEXD0077 were archived.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Covered clinical indications
    6 monthsPrimary HLH authorization limit
    12 monthsHLH/MAS authorization limit
    Not coveredSecondary HLH
    J9210HCPCS code

    Coverage Criteria

    Primary HLH

    Covered when all applicable criteria are met.

    • Confirmation of primary HLH

      • Known causative mutation: A gene mutation known to cause primary HLH is confirmed, such as PRF1, UNC13D, RAB27A, STX11, or STXBP2.
      • Clinical characteristics: Five clinical characteristics are documented: fever, splenomegaly, two cytopenias in peripheral blood, and one additional HLH characteristic.Five characteristics total

        The two-cytopenia requirement includes hemoglobin < 9 g/dL, platelet count < 100 x 10^9/L, or neutrophils < 1 x 10^9/L. Additional characteristics include hypertriglyceridemia or hypofibrinogenemia, hemophagocytosis without malignancy, low or absent natural killer cell activity, ferritin ≥ 500 mcg/L, or soluble CD25 ≥ 2,400 U/mL.

    Primary HLH with hematopoietic stem cell transplant

    Covered when all criteria are met.

    Primary HLH with hematopoietic stem cell transplant: The patient has refractory, recurrent, or progressive primary HLH, or intolerance to conventional HLH therapy; Gamifant is administered with dexamethasone; the patient is a candidate for hematopoietic stem cell transplant; Gamifant is used during the induction or maintenance phase of transplant and will be discontinued at the initiation of conditioning; the provider does not request a planned inpatient admission solely to administer Gamifant; dosing follows FDA-approved labeling; and authorization is for no more than 6 months.Authorization ≤ 6 months

    Initial therapy for HLH/MAS associated with Still's disease

    Initial therapy is covered when all criteria are met.

    Initial HLH/MAS associated with Still's disease

    • MAS laboratory criteria

      • Platelet count is ≤ 181 x 10^9/L.≤ 181 x 10^9/L
      • AST is > 48 U/L.> 48 U/L
      • Triglycerides are > 156 mg/dL.> 156 mg/dL
      • Fibrinogen is ≤ 360 mg/dL.

    Continuation therapy for HLH/MAS

    Continuation therapy is covered when all criteria are met.

    Continuation HLH/MAS associated with Still's disease: Documentation shows a positive clinical response to Gamifant; the provider does not request a planned inpatient admission solely to administer Gamifant; dosing follows FDA-approved labeling; and reauthorization is for no more than 12 months.Reauthorization ≤ 12 months

    Secondary hemophagocytic lymphohistiocytosis (HLH) is not proven or medically necessary for Gamifant treatment.

    Gamifant is not proven or medically necessary for the treatment of secondary HLH.

    Coding and Clinical Thresholds

    HCPCS CodeHCPCS
    J9210Injection, emapalumab-lzsg, 1 mg
    Diagnosis CodeICD-10
    D76.1Hemophagocytic lymphohistiocytosis
    D76.2Hemophagocytic syndrome, infection-associated
    D76.3Other histiocytosis syndromes
    Primary HLH cytopenia
    MeasureHemoglobin
    Threshold< 9 g/dL
    ApplicationOne of the cytopenias used to confirm primary HLH
    Primary HLH cytopenia
    MeasurePlatelet count
    Threshold< 100 x 10^9/L
    ApplicationOne of the cytopenias used to confirm primary HLH

    Authorization and Provider Requirements

    Prior Authorization

    Primary HLH Prior Authorization

    Prior authorization is required for Gamifant for primary hemophagocytic lymphohistiocytosis (HLH). Coverage requires the applicable primary HLH criteria, FDA-approved dosing, and authorization within the permitted period.

    • Confirmed diagnosis of primary HLH.
    • Dosing must be in accordance with FDA-approved labeling.
    • Authorization will be for no more than 6 months.
    Prior Authorization

    Initial HLH/MAS Authorization

    For initial treatment of HLH/macrophage activation syndrome (MAS) associated with Still's disease, submit a request meeting all applicable clinical and dosing requirements.

    • Diagnosis of HLH/MAS.
    • Known or suspected Still's disease, including systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still's disease (AOSD).
    • Dosing must be in accordance with FDA-approved labeling.

    Clinical Background

    Primary hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of immune dysregulation and hyperinflammation. It typically presents in infancy and is associated with high mortality.

    Definitions

    Definition
    DefinitionHypertriglyceridemia
    SpecimenFasting triglycerides
    CriterionAt least 3 mmol/L or at least 265 mg/dL
    Definition
    DefinitionHypofibrinogenemia
    MeasureFibrinogen level
    CriterionNo greater than 1.5 g/L

    Initial Therapy Criteria

    Primary HLH initial therapy

    Initial therapy for primary HLH requires all applicable criteria.

    Primary HLH initial therapy: Primary HLH is confirmed; disease is refractory, recurrent, or progressive, or the patient is intolerant of conventional HLH therapy; dosing follows FDA-approved labeling; and authorization is for no more than 6 months.Authorization ≤ 6 months

    Conventional therapy examples include etoposide, corticosteroids, cyclosporine, anti-thymocyte globulin, and methotrexate.

    HLH/MAS initial therapy

    Initial therapy for HLH/MAS associated with Still's disease requires all criteria.

    • MAS laboratory criteria

      • Platelet count is ≤ 181 x 10^9/L.

    Continuation Criteria

    HLH/MAS continuation

    Continuation therapy requires all criteria below.

    Continuation therapy: A positive clinical response to Gamifant is documented; the provider does not request a planned inpatient admission solely to administer Gamifant; dosing follows FDA-approved labeling; and reauthorization is for no more than 12 months.Reauthorization ≤ 12 months

    Required Prior Therapy

    StepRequired prior therapyRequired outcome
    1Conventional HLH therapy, such as etoposide, corticosteroids, cyclosporine, anti-thymocyte globulin, or methotrexateDisease is refractory, recurrent, or progressive, or the patient is intolerant of the therapy
    StepRequired prior therapyRequired outcome
    1Glucocorticoid therapy, specifically high-dose intravenous glucocorticoidsInadequate response or intolerance

    Authorization Duration Limits

    Authorization duration
    DrugGamifant
    UsePrimary HLH
    Maximum authorizationNo more than 6 months
    Authorization duration
    DrugGamifant
    UseHLH/MAS associated with Still's disease
    Maximum durationInitial authorization or reauthorization no more than 12 months

    Site-of-Care Requirements

    Billing Rule

    Use hospital outpatient care for planned administration

    The provider must not request a planned inpatient admission for the sole purpose of administering Gamifant. This site-of-care restriction applies to Gamifant administration in the hospital outpatient setting.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyGamifant (emapalumab-lzsg) Coverage
    Policy CodePolicy 2026D0077L
    Change TypeAdministrative updateno material clinical or coverage changes
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records, such as chart notes and laboratory values, confirming the applicable diagnosis and required clinical or laboratory criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Provider RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaRequired Prior TherapyAuthorization Duration LimitsSite-of-Care Requirements
    ≤ 360 mg/dL
    Primary HLH cytopenia
    MeasureNeutrophils
    Threshold< 1 x 10^9/L
    ApplicationOne of the cytopenias used to confirm primary HLH
    MAS laboratory criterion
    MeasureFerritin
    Threshold> 684 ng/mL
    ApplicationActive MAS criterion
    MAS laboratory criterion
    MeasurePlatelet count
    Threshold≤ 181 x 10^9/L
    ApplicationOne of four laboratory criteria for active MAS
    MAS laboratory criterion
    MeasureAST
    Threshold> 48 U/L
    ApplicationOne of four laboratory criteria for active MAS
    MAS laboratory criterion
    MeasureTriglycerides
    Threshold> 156 mg/dL
    ApplicationOne of four laboratory criteria for active MAS
    MAS laboratory criterion
    MeasureFibrinogen
    Threshold≤ 360 mg/dL
    ApplicationOne of four laboratory criteria for active MAS
    HLH laboratory characteristic
    TermHypertriglyceridemia
    SpecimenFasting triglycerides
    Threshold≥ 3 mmol/L or ≥ 265 mg/dL
    HLH laboratory characteristic
    TermHypofibrinogenemia
    MeasureFibrinogen
    Threshold≤ 1.5 g/L
    HLH laboratory characteristic
    MeasureFerritin
    Threshold≥ 500 mcg/L
    ApplicationOne of the additional clinical characteristics listed for primary HLH confirmation
    HLH laboratory characteristic
    MeasureSoluble CD25 (soluble IL-2 receptor)
    Threshold≥ 2,400 U/mL
    ApplicationOne of the additional clinical characteristics listed for primary HLH confirmation
    Active MAS study enrollment
    MeasureFerritin
    Threshold> 684 ng/mL
    ApplicationActive MAS study enrollment criterion
    Active MAS study enrollment
    MeasurePlatelet count
    Threshold≤ 181 × 10^9/L
    ApplicationOne of four active MAS study enrollment laboratory criteria
    Active MAS study enrollment
    MeasureAST
    Threshold> 48 U/L
    ApplicationOne of four active MAS study enrollment laboratory criteria
    Active MAS study enrollment
    MeasureTriglycerides
    Threshold> 156 mg/dL
    ApplicationOne of four active MAS study enrollment laboratory criteria
    Active MAS study enrollment
    MeasureFibrinogen
    Threshold≤ 360 mg/dL
    ApplicationOne of four active MAS study enrollment laboratory criteria
    Complete response ferritin endpoint
    EndpointFerritin reduction
    Response thresholdDecreased ≥ 80% from screening or baseline, whichever was higher, or < 2000 ng/mL, whichever was lower
    ApplicationFerritin component of the complete response endpoint
  1. Initial approval will be for no more than 12 months.
  2. Unsupported block type: prior_auth堆?

    Documentation Required

    Failure or Intolerance of Conventional HLH Therapy

    For primary HLH, document that the disease is refractory, recurrent, or progressive, or that the patient is intolerant of conventional HLH therapy. Examples of conventional therapy include etoposide, corticosteroids, cyclosporine, anti-thymocyte globulin, and methotrexate.

    • Submit documentation of failure, recurrence, progression, or intolerance with conventional HLH therapy.
    • Applicable conventional therapies may include etoposide, corticosteroids, cyclosporine, anti-thymocyte globulin, or methotrexate.
    Documentation Required

    Inadequate Glucocorticoid Response

    For HLH/MAS associated with Still's disease, document inadequate response to glucocorticoids or glucocorticoid intolerance. The clinical record must specifically address response to high-dose intravenous glucocorticoids.

    • Inadequate response or intolerance to glucocorticoids is required for initial therapy.
    • Document inadequate response to high-dose intravenous glucocorticoids.
    Documentation Required

    Medical Records and Laboratory Confirmation

    Submit medical records, such as chart notes and laboratory values, confirming the diagnosis and required clinical or laboratory findings for the applicable indication.

    • For primary HLH, records must confirm either a gene mutation known to cause primary HLH, such as PRF1, UNC13D, RAB27A, STX11, or STXBP2, or five specified clinical characteristics.
    • Primary HLH clinical findings include fever, splenomegaly, and at least two cytopenias: hemoglobin < 9 g/dL, platelet count < 100 × 10^9/L, or neutrophils < 1 × 10^9/L.
    • For Still's disease-associated MAS, records must confirm sJIA or AOSD and active MAS with ferritin > 684 ng/mL plus at least two of the following: platelet count ≤ 181 × 10^9/L, AST > 48 U/L, triglycerides > 156 mg/dL, or fibrinogen ≤ 360 mg/dL.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, submit records demonstrating that the patient has had a positive clinical response to Gamifant.

    • Clinical documentation must support the patient's positive response to ongoing Gamifant therapy.
    Denial Risk

    Secondary HLH Not Covered

    Gamifant is not proven or medically necessary for the treatment of secondary HLH.

    • Requests for treatment of secondary HLH are not covered under this policy.
    Denial Risk

    Planned Inpatient-Only Administration

    Do not request a planned inpatient admission solely to administer Gamifant. This restriction applies to both primary HLH and Still's disease-associated HLH/MAS requests.

    • Gamifant administration must not be the sole purpose of a planned inpatient admission.
    • For primary HLH, also document that the patient is a hematopoietic stem cell transplant candidate and that Gamifant is being used during the induction or maintenance phase of transplant, with discontinuation at initiation of conditioning.
    Denial Risk

    Failure to Meet Clinical Criteria

    Requests that do not meet the applicable clinical, documentation, laboratory, transplant, administration, dosing, or authorization-period requirements are not covered.

    • Include all required diagnosis and disease-status documentation.
    • Meet applicable conventional-therapy, glucocorticoid-response, laboratory, and transplant criteria.
    • Use FDA-approved dosing and observe the applicable 6-month or 12-month authorization limit.
    • Do not request planned inpatient admission solely for Gamifant administration.
    Complete response
    EndpointComplete response
    Clinical componentClinical resolution of MAS signs and symptoms, with a visual analogue scale of ≤ 1 cm
    Laboratory componentWBC count and platelet count above the lower limit of normal; LDH, AST, and ALT below 1.5× the upper limit of normal; fibrinogen > 100 mg/dL; and ferritin decreased ≥ 80% from screening or baseline, whichever was higher, or < 2000 ng/mL, whichever was lower
    ≤ 181 x 10^9/L
  3. AST is > 48 U/L.> 48 U/L
  4. Triglycerides are > 156 mg/dL.> 156 mg/dL
  5. Fibrinogen is ≤ 360 mg/dL.≤ 360 mg/dL